Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Cardinal Health Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.36, while Cardinal Health Inc trades at $237.87 (market cap $56.14B). The key difference: Cardinal Health Inc pays a 0.85% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | CAH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $239.71 |
52-Week Low | $43.28 | $146.04 |
Market Cap | — | $56.14B |
Enterprise Value | — | $61.12B |
Dividend Yield | — | 0.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Cardinal Health (CAH) trades at $239.71, up 0.32% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats, including Q1 2026 EPS of $3.17 beating estimates of $2.79. Revenue reached $222.58B in 2025 with net income of $1.56B. Technical indicators are bullish, with the current price above key support levels. Analysts maintain a positive outlook with a consensus price target of $243.33.
CAH presents a compelling investment case driven by earnings growth and defensive healthcare distribution. However, risks include high debt levels, thin profit margins, and competitive pressures. The stock's valuation at a P/E of 36.26 may limit upside if growth moderates. Overall, the bullish analyst consensus and operational strength support a positive medium-term view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
